Long-term effects of non-retrieved inferior vena cava filters on recurrences of venous thromboembolism in cancer and non-cancer patients: From the COMMAND VTE registry
Toru Takase,Yoshitaka Iwanaga,Yugo Yamashita,Takeshi Morimoto,Yusuke Yoshikawa,Hidewo Amano,Seiichi Hiramori,Kitae Kim,Maki Oi,Yohei Kobayashi,Yuji Nishimoto,Heitaro Watanabe,Kenji Yamaji,Ryobun Yasuoka,Masafumi Ueno,Kazuhiro Kobuke,Takeshi Kimura,Shunichi Miyazaki,COMMAND VTE Registry Investigators
DOI: https://doi.org/10.1016/j.ejim.2020.09.002
Abstract:Background: There is a paucity of data comparing the long-term outcomes after inferior vena cava (IVC) filters placement for patients with acute venous thromboembolism (VTE) between those with and without active cancer. Methods: In the COMMAND VTE Registry, we evaluated the effects of IVC filter use on the long-term clinical outcomes stratified by the presence and absence of active cancer. Results: Among 2,626 patients with acute symptomatic VTE, there were 604 patients with active cancer, and 2022 patients without active cancer. IVC filters were placed and not retrieved in 455 patients (17%) in the entire cohort, in 150 patients (24.8%) in the active cancer stratum, and in 305 patients (15.1%) in the non-cancer stratum. In the entire cohort, non-retrieved IVC filter placement was not associated with a lower adjusted risk for PE recurrence (HR 0.59, 95% CI 0.30-1.15, P = 0.122), but with an increased adjusted risk for DVT recurrence (HR 2.27, 95% CI 1.43-3.60, P<0.001). In the non-cancer stratum, the non-retrieved IVC filter placement was associated with a decreased risk for PE (HR 0.29, 95% CI 0.09-0.93, P = 0.037), but not with an increased risk for DVT (HR 1.73, 95% CI 0.89-3.38, P = 0.108), while in the active cancer stratum, it was associated with an increased risk for DVT (HR 2.47, 95% CI 1.24-4.91, P = 0.010), but not with a decreased risk for PE (HR 0.82, 95% CI 0.34--1.96, P = 0.650). Conclusions: There were some differences in the risk-benefit balance between VTE patients with and without active cancer.